TY - JOUR
T1 - High-dose therapy and autologous bone marrow transplantation for adult patients with lymphoblastic lymphoma
T2 - Results of the European group for bone marrow transplantation
AU - Sweetenham, John W.
AU - Liberti, Grace
AU - Pearce, Rachel
AU - Taghipour, Golnaz
AU - Santini, Gino
AU - Goldstone, Anthony H.
PY - 1994/7
Y1 - 1994/7
N2 - Purpose: To investigate the results of treatment and factors that affect prognosis in adult patients undergoing high-dose therapy and autologous bone marrow transplantation (ABMT) for lymphoblastic lymphoma (LBL). Patients and Methods: The study was a retrospective analysis of 214 patients reported to the Lymphoma Registry of the European Group for Bone Marrow Transplantation (EBMT) between January 1981 and December 1992, including 105 patients undergoing marrow transplantation in first complete remission (CR). Data on all patients were reviewed, and analysis of prognostic factors conducted. Results: The actuarial overall survival rate at 6 years for the entire group is 42%. Disease status at ABMT was the major determinant of outcome: 6-year actuarial overall survival was 63% for patients transplanted in first CR, compared with 15% for those with resistant disease at the time of transplantation. Transplantation in second CR resulted in a 31% rate of actuarial overall survival at 6 years. For patients transplanted in first CR, univariate analysis failed to identify any factors at presentation that predicted for outcome after transplantation. Conclusion: These results suggest that ABMT is effective therapy for adults with LBL, even in patients with disease that is resistant to conventional-dose therapy. Results for patients transplanted in second CR are superior to those reported for conventional-dose salvage regimens. The results in first CR require verification in a prospective randomized clinical study.
AB - Purpose: To investigate the results of treatment and factors that affect prognosis in adult patients undergoing high-dose therapy and autologous bone marrow transplantation (ABMT) for lymphoblastic lymphoma (LBL). Patients and Methods: The study was a retrospective analysis of 214 patients reported to the Lymphoma Registry of the European Group for Bone Marrow Transplantation (EBMT) between January 1981 and December 1992, including 105 patients undergoing marrow transplantation in first complete remission (CR). Data on all patients were reviewed, and analysis of prognostic factors conducted. Results: The actuarial overall survival rate at 6 years for the entire group is 42%. Disease status at ABMT was the major determinant of outcome: 6-year actuarial overall survival was 63% for patients transplanted in first CR, compared with 15% for those with resistant disease at the time of transplantation. Transplantation in second CR resulted in a 31% rate of actuarial overall survival at 6 years. For patients transplanted in first CR, univariate analysis failed to identify any factors at presentation that predicted for outcome after transplantation. Conclusion: These results suggest that ABMT is effective therapy for adults with LBL, even in patients with disease that is resistant to conventional-dose therapy. Results for patients transplanted in second CR are superior to those reported for conventional-dose salvage regimens. The results in first CR require verification in a prospective randomized clinical study.
UR - http://www.scopus.com/inward/record.url?scp=0028341009&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028341009&partnerID=8YFLogxK
U2 - 10.1200/JCO.1994.12.7.1358
DO - 10.1200/JCO.1994.12.7.1358
M3 - Article
C2 - 8021726
AN - SCOPUS:0028341009
SN - 0732-183X
VL - 12
SP - 1358
EP - 1365
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 7
ER -